Clinical Trial Update: Dupilumab in Eosinophilic Gastritis [Phase 2]

View source ↗

Summary

Phase 2 trial of Dupixent (dupilumab) for eosinophilic gastritis and eosinophilic gastroenteritis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Gastritis
• Eosinophilic Gastroenteritis

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | Status: COMPLETED | Results posted: 2025-11-04